Skip to main
OFIX

Orthofix International (OFIX) Stock Forecast & Price Target

Orthofix International (OFIX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 25%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Orthofix Medical is likely to remain a strong player in the medical device industry, driven by its diverse product portfolio and strategic focus on both global spine and limb reconstruction segments. However, the company's recent streamlining activities and litigation costs may impact its overall financial performance in the short term. In the long term, Orthofix's 2028 target for adjusted EBITDA margin shows potential for growth and solid cash flow generation, leading to a maintained OUTPERFORM rating with a price target of $17 (calculated using 8.5x multiple on 2026 adjusted EBITDA estimate).

Bears say

Orthofix Medical is struggling with headwinds and uncertainties related to the impact of recent Medicare pricing cuts on its bone growth stimulator business. Despite making some organizational changes, the company's preliminary revenue results for Q1/26 suggest that its performance may not meet the expectations of analysts, which could lead to further downward revisions in its guidance for the year. The company showed overall solid performance, but its cash flow and adjusted EBITDA margin guidance for FY/26 and FY/27 was disappointing.

Orthofix International (OFIX) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 25% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Orthofix International and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Orthofix International (OFIX) Forecast

Analysts have given Orthofix International (OFIX) a Buy based on their latest research and market trends.

According to 4 analysts, Orthofix International (OFIX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Orthofix International (OFIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.